The outlook revision reflects Baxter’s continued volatility in operations and Moody’s Investors Service’s expectation that liquidity will remain constrained.
Moody’s also affirmed Baxter’s “Baa2” rating, affecting $41.8 million of debt. The rating affirmation is based on Baxter’s solid market position but remains constrained by Baxter’s small size.
More articles on healthcare finance:
231 hospitals inadvertently earned Medicare bonuses despite lower quality care
Harvard study finds consumer price shopping doesn’t lower healthcare costs
Fitch: As acquisitions continue, healthcare leverage increases
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
